object
antimicrobi
stewardship
program
asp
ensur
appropri
antibiot
use
reduc
health
care
cost
minim
antibiot
resist
nation
asthma
guidelin
recommend
antibiot
exacerb
unless
child
infect
comorbid
american
academi
pediatr
aap
establish
benchmark
unjustifi
antibiot
use
retrospect
studi
institut
show
antibiot
prescrib
without
justif
children
admit
asthma
purpos
studi
reduc
unjustifi
antibiot
use
institut
children
asp
direct
toward
asthma
studi
period
last
novemb
march
children
month
year
age
admit
asthma
exacerb
includ
comorbid
exclud
multidisciplinari
team
pediatr
pharmacotherapi
pulmonolog
emerg
depart
ed
infecti
diseas
qualiti
improv
form
focu
process
improv
intervent
execut
seri
plandostudyact
cycl
cycl
asthma
guidelin
appropri
antibiot
use
dissemin
pediatr
hous
staff
post
pediatr
unit
cycl
encompass
present
asp
guidelin
pediatr
ed
staff
cycl
consist
journal
club
pulmonari
divis
discuss
role
azithromycin
asthma
exacerb
cycl
twentyfour
patient
review
novemb
antibiot
prescrib
children
unjustifi
rate
cycl
twentythre
patient
review
decemb
januari
prescrib
antibiot
unjustifi
rate
cycl
februari
march
twentyon
children
review
antibiot
prescrib
children
justifi
total
patient
includ
studi
unjustifi
antibiot
prescrib
rate
reduct
conclus
asp
surpass
benchmark
set
aap
guidelin
reduc
percentag
unjustifi
antibiot
children
asthma
accord
infecti
diseas
societi
america
role
antimicrobi
stewardship
program
asp
ensur
appropri
antimicrobi
therapi
order
optim
clinic
outcom
decreas
associ
advers
event
inappropri
antibiot
prescrib
may
lead
advers
effect
antibiot
antibiot
resist
health
care
cost
pediatr
popul
overprescrib
antibiot
report
condit
asthma
bronchiol
de
boeck
et
al
discov
belgian
children
receiv
medic
asthma
prescrib
antibiot
often
without
asthma
medic
vs
respect
vanderweil
et
al
review
emerg
depart
ed
asthma
visit
patient
year
age
found
antibiot
prescrib
instanc
unjustifi
rate
paul
et
al
found
unjustifi
antibiot
rate
popul
ambulatori
care
children
asthma
number
author
translat
million
million
pediatr
visit
asthma
unit
state
children
comorbid
nation
heart
lung
blood
institut
nhlbi
global
initi
asthma
gina
guidelin
propos
asthma
exacerb
routin
treat
antibiot
antibiot
prescrib
justifi
basi
comorbid
may
worsen
patient
outcom
fever
purul
sputum
bacteri
sinus
andor
evid
pneumonia
patient
document
infect
varieti
factor
may
contribut
widespread
pattern
unjustifi
antibiot
use
infant
present
wheez
antibiot
may
prescrib
asthma
diagnosi
confound
viralinduc
bronchiol
radiolog
find
suggest
pneumonia
diagnost
uncertainti
may
drive
antibiot
prescrib
patient
present
fever
object
sign
infect
elev
white
blood
cell
count
marker
infect
physician
may
also
provid
antibiot
without
clear
bacteri
find
owe
fear
readmiss
avoid
medicalleg
issu
relat
miss
infecti
diagnosi
initi
present
parent
may
also
request
antibiot
prescrib
child
present
like
viral
infect
caus
antibioticprescrib
pressur
clinic
varianc
antibiot
prescrib
asthma
exacerb
led
american
academi
pediatr
aap
establish
benchmark
care
unjustifi
use
institut
lee
elchaar
retrospect
examin
antibiot
prescrib
children
admit
asthma
timefram
includ
anoth
asp
intervent
respiratori
syncyti
viru
rsv
bronchiol
follow
intervent
period
author
found
patient
receiv
antibiot
receiv
antibiot
justif
object
current
studi
implement
asp
target
specif
asthma
children
aim
reduc
unjustifi
antibiot
prescrib
differ
implement
asp
plandostudyact
pdsa
cycl
allow
time
assess
impact
intervent
nyu
winthrop
hospit
children
medic
center
consist
pediatr
bed
within
larg
adult
acut
care
hospit
studi
concurr
chart
review
design
took
place
gener
pediatr
pediatr
intens
care
unit
picu
pediatr
ed
novemb
march
timefram
mirror
month
previou
retrospect
studi
institut
review
board
design
qualiti
improv
qi
project
exempt
review
inclus
criteria
children
age
month
younger
year
admit
asthma
exacerb
exclus
criteria
comorbid
would
justifi
antibiot
use
chronic
lung
diseas
cystic
fibrosi
neuromuscular
disord
syndrom
children
receiv
antibiot
anoth
institut
prior
admiss
hospit
also
exclud
concurr
chart
review
identifi
patient
review
daili
censu
gener
pediatr
pediatr
intens
care
unit
children
admit
asthma
exacerb
demograph
data
collect
includ
age
sex
weight
comorbid
allergi
data
collect
pertain
admiss
includ
length
stay
maximum
temperatur
max
home
temperatur
admiss
max
first
hour
admiss
prior
antibiot
system
corticosteroid
use
white
blood
cell
count
neutrophil
immatur
neutrophil
band
blood
urin
cultur
result
chest
xray
find
film
array
panel
result
antibiot
agent
use
prescrib
day
therapi
antibiot
start
applic
whether
use
justifi
develop
institut
guidelin
appropri
indic
antibiot
prescrib
asthma
exacerb
accord
nhlbi
gina
asthma
guidelin
figur
definit
justifi
includ
child
fever
purul
sputum
bacteri
sinus
evid
pneumonia
document
infect
specif
multidisciplinari
asthma
asp
team
develop
consist
pharmaci
resid
pediatr
pharmacotherapist
pediatr
pulmonologist
pediatr
infecti
diseas
specialist
qi
offic
member
pediatr
ed
asp
team
met
initi
determin
implement
program
cycl
final
time
conclus
research
meet
discuss
find
identifi
area
need
futur
intervent
use
pdsa
cycl
decis
made
consensu
stakehold
suggest
commun
meet
via
email
asp
carri
seri
pdsa
cycl
assess
impacteffect
intervent
real
time
use
spearhead
next
step
process
continu
divid
cycl
phase
consist
develop
specif
pediatr
asthma
asp
multidisciplinari
team
institut
antibiot
guidelin
studi
phase
determin
whether
last
cycl
intervent
effect
evalu
carri
concurr
determin
antibiot
justif
perform
review
daili
patient
censu
meet
multidisciplinari
team
pharmaci
resid
perform
weekli
audit
feedback
case
resid
review
admiss
weekli
basi
assess
antibiot
justif
accord
guidelin
discuss
health
care
team
need
feedback
provid
prescrib
discontinu
antibiot
unjustifi
addit
period
remind
asp
result
place
bulletin
board
gener
pediatr
picu
area
involv
brief
remind
guidelin
review
asthma
exacerb
case
week
provid
feedback
prescrib
regard
justif
antibiot
prescrib
find
phase
serv
aim
next
intervent
process
may
consist
sever
pdsa
cycl
ultim
achiev
studi
goal
pdsa
cycl
novemb
first
plan
phase
encompass
result
prior
institut
review
antibiot
use
children
admit
asthma
review
show
incid
unjustifi
antibiot
use
serv
justif
phase
involv
present
institut
asthma
guidelin
pediatr
hous
staff
visual
remind
guidelin
along
result
audit
post
bulletin
board
unit
data
analysi
cycl
show
patient
receiv
unjustifi
antibiot
therapi
start
therapi
ed
therefor
object
cycl
address
set
pdsa
cycl
cycl
occur
decemb
januari
intervent
includ
present
asp
institut
asthma
guidelin
pediatr
ed
staff
consist
ed
chief
physician
nurs
monthli
staff
meet
meet
becam
appar
institut
sepsi
protocol
significantli
influenc
use
antibiot
ed
exampl
child
present
ed
symptom
asthma
elev
lactat
concentr
sign
symptom
bacteri
infect
receiv
sepsi
workup
includ
antibiot
per
sepsi
protocol
understand
practic
ed
staff
discuss
allow
asp
deem
prescrib
justifi
pdsa
cycl
plan
phase
reli
find
previou
cycl
pulmonari
servic
prescrib
antibiot
patient
without
justif
review
antibiot
prescrib
point
azithromycin
use
frequent
follow
ceftriaxon
take
find
account
cycl
object
work
pediatr
pulmonari
divis
cycl
occur
februari
march
follow
journal
club
member
asp
pediatr
pulmonari
divis
met
discuss
use
azithromycin
patient
asthma
meet
becam
appar
barrier
servic
identif
atyp
infect
name
mycoplasma
pneumonia
chlamydia
spp
patient
admit
asthma
exacerb
improv
despit
standard
care
pulmonologist
assum
atyp
microorgan
play
role
prescrib
azithromycin
pulmonologist
incorrectli
inform
mycoplasma
titer
perform
week
fact
drawn
twice
weekli
therefor
patient
suspect
atyp
microorgan
period
test
pass
patient
test
place
empir
azithromycin
requir
educ
pulmonolog
depart
review
result
intervent
thereaft
key
driver
diagram
reflect
key
driver
stakehold
contribut
intervent
figur
process
measur
studi
number
antibiot
prescrib
children
admit
asthma
exacerb
outcom
measur
unjustifi
antibiot
rate
novemb
march
total
children
satisfi
entri
criteria
studi
ten
patient
exclud
basi
comorbid
tabl
henc
sampl
size
consist
children
admit
asthma
exacerb
averag
patient
age
entir
cohort
year
older
children
greater
number
male
children
cycl
tabl
virus
isol
time
admiss
display
tabl
multiplex
film
array
panel
biofir
biofir
diagnost
llc
salt
lake
citi
ut
n
children
test
posit
rhinoviru
enteroviru
follow
rsv
n
coronaviru
n
metapneumoviru
n
adenoviru
n
parainfluenza
n
influenza
n
patient
demograph
display
tabl
cycl
cycl
twentyfour
pediatr
visit
asthma
exacerb
review
antibiot
prescrib
visit
unjustifi
figur
first
patient
prescrib
antibiot
without
justif
present
asthma
exacerb
afebril
clear
lung
field
chest
radiograph
film
array
posit
rhinovirusenteroviru
identifi
mycoplasma
pneumonia
patient
receiv
azithromycin
day
start
ed
discontinu
restart
pulmonari
servic
owe
suspicion
atyp
pneumonia
caus
mycoplasma
spp
howev
titer
never
sent
justifi
diagnosi
second
patient
present
asthma
exacerb
fever
rectal
chest
radiograph
read
consist
reactiv
airway
diseas
viru
film
array
panel
posit
rhinovirusenteroviru
child
receiv
dose
ceftriaxon
ed
cycl
decemb
patient
review
prescrib
antibiot
patient
receiv
antibiot
without
justif
first
patient
decemb
present
asthma
exacerb
fever
posit
rhinovirusenteroviru
normal
chest
radiograph
patient
receiv
dose
ceftriaxon
ed
start
azithromycin
gener
pediatr
floor
patient
primari
physician
dose
given
without
justif
base
present
find
second
patient
fever
admiss
first
hour
admiss
film
array
posit
coronaviru
rsv
evid
pulmonari
opac
chest
radiograph
patient
given
dose
amoxicillin
accord
primari
pediatrician
treat
acut
otiti
media
howev
sinc
patient
admiss
normal
bilater
tympan
membran
rule
otiti
media
amoxicillin
discontinu
cycl
extend
januari
patient
enrol
receiv
antibiot
justifi
reveal
unjustifi
rate
cycl
februari
march
twentyon
children
admit
antibiot
prescrib
children
respect
case
antibiot
prescrib
justifi
show
incid
unjustifi
use
popul
demograph
laboratori
data
display
tabl
total
readmiss
occur
howev
none
due
infect
patient
receiv
antibiot
without
justif
administ
ceftriaxon
receiv
azithromycin
anoth
receiv
amoxicillin
analysi
use
reduc
unjustifi
antibiot
children
asthma
dorzin
se
et
al
figur
key
driver
diagram
run
chart
depict
figur
total
children
studi
receiv
antibiot
unjustifi
use
overal
rate
unjustifi
antibiot
use
drop
reduct
previou
research
area
institut
high
percentag
antibiot
use
without
justif
children
asthma
exacerb
baselin
rapid
pdsa
cycl
asp
surpass
benchmark
set
aap
reduc
percentag
unjustifi
antibiot
children
asthma
encourag
later
cycl
unjustifi
antibiot
use
baselin
valu
studi
might
influenc
prior
asp
program
institut
reduc
antibiot
use
other
report
rate
unjustifi
antibiot
use
without
asp
intervent
rang
knowledg
first
qi
project
implement
asp
toward
asthma
use
pdsa
cycl
overal
antibiot
prescrib
frequent
institut
report
paul
et
al
vanderweil
et
al
studi
gather
data
retrospect
year
use
nation
survey
identifi
patient
code
data
collect
patient
month
year
rate
asthma
infect
expect
high
chose
period
time
achiev
highest
impact
reduc
antibiot
use
enrol
patient
cours
year
possibl
rate
antibiot
prescrib
might
similar
author
also
aim
evalu
patient
concurr
discuss
antibiot
need
health
care
team
member
real
time
process
take
consider
amount
time
explain
smaller
sampl
size
key
compon
asp
program
educ
time
feedback
multidisciplinari
approach
help
us
achiev
lower
unjustifi
antibiot
rate
gener
pediatr
floor
picu
ed
inform
dissemin
staff
believ
chang
prescrib
pattern
provid
due
asp
complet
asp
ceftriaxon
agent
commonli
use
follow
azithromycin
studi
greater
incid
macrolid
use
asid
evalu
unjustifi
use
notic
overal
azithromycin
prescrib
patient
commonli
cycl
impel
us
reevalu
role
manag
acut
exacerb
recent
studi
stokholm
et
al
azithromycin
use
asthmalik
symptom
children
studi
random
doubleblind
placebocontrol
trial
shorten
durat
symptom
arm
receiv
azithromycin
compar
placebo
find
suggest
use
azithromycin
benefici
set
still
could
confirm
evid
provid
azithromycin
believ
act
antiinflammatori
agent
demonstr
cystic
fibrosi
would
intrigu
demonstr
whether
degre
inflamm
patient
asthma
match
seen
cystic
fibrosi
therebi
justifi
role
azithromycin
studi
done
particular
cohort
subject
close
monitor
physician
therefor
result
extrapol
gener
reduc
unjustifi
antibiot
children
asthma
comorbid
eczema
atop
dermat
kabuki
syndrom
development
delay
prurit
rash
eczema
obes
gerd
scoliosi
seizur
disord
osa
mrcp
eczema
allerg
rhiniti
eczema
popul
strength
studi
pdsa
cycl
methodolog
close
followup
impact
intervent
concurr
chart
review
design
well
audit
feedback
allow
effect
intervent
monitor
real
time
multidisciplinari
approach
help
execut
intervent
occur
effici
work
differ
specialti
help
us
identifi
barrier
antibiot
prescript
differ
perspect
allow
collabor
effort
overcom
issu
limit
studi
smaller
sampl
size
compar
baselin
data
children
review
well
previou
studi
examin
antibiot
prescrib
popul
attribut
concurr
data
collect
process
therefor
miss
patient
admit
pharmaci
resid
attend
assess
antibiot
prescrib
period
month
expect
largest
number
admiss
due
asthma
infect
collect
patient
studi
could
expand
remaind
year
perhap
year
anoth
limit
asp
misunderstand
time
mycoplasma
titer
report
institut
case
film
array
detect
mycoplasma
recommend
perform
titer
physician
believ
titer
perform
week
oppos
twice
week
led
delay
prompt
diagnosi
physician
caus
organ
delay
analysi
team
determin
whether
antibiot
justifi
import
note
way
confirm
mycoplasma
infect
either
presenc
posit
polymeras
chain
reaction
increas
mycoplasma
titer
drawn
week
apart
someth
done
patient
thu
sole
use
serolog
one
point
time
done
institut
provid
accur
diagnosi
mycoplasma
assist
make
decis
treat
qi
effort
import
work
toward
sustain
achiev
made
futur
continu
assess
antibiot
prescrib
children
present
asthma
exacerb
determin
varianc
period
remind
guidelin
formul
help
keep
practic
forefront
physician
prescrib
implic
studi
educ
evalu
asp
prescrib
pattern
fact
improv
set
asthma
led
decreas
unjustifi
prescrib
antibiot
believ
turn
improv
clinic
outcom
ensur
appropri
antibiot
use
minim
antibiot
resist
reduc
health
care
cost
though
guidelin
recommend
use
antibiot
asthma
exacerb
children
practic
persist
enough
aap
set
benchmark
antibiot
use
pdsa
cycl
time
audit
feedback
period
month
allow
us
meet
aap
benchmark
reduc
antibiot
prescrib
everi
effort
reduc
inappropri
antibiot
prescrib
contribut
reduc
advers
effect
antibiot
antibiot
resist
pdsa
plandostudyact
reduct
inappropri
use
antibiot
effort
dissemin
inform
asp
asthma
shown
success
suggest
method
prevent
inappropri
use
